Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands

Breast Cancer Research and Treatment

Volumn 129, Issue 1, 2011, Pages 229-233

  De Munck, L ^a   Schaapveld, M ^b   Siesling, S ^a,c   Wesseling, J ^b   Voogd, A C ^d,e   Tjan Heijnen, V C G ^d   Otter, R ^a   Willemse, P H B ^f  

^a Integraal Kankercentrum Noord Nederland   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e Eindhoven   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adjuvant; Breast cancer; Guideline; HER2; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER REGISTRY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DRUG CONTRAINDICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT REFUSAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NETHERLANDS; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 79960842311     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1451-0     Document Type: Article

References (14)

1. Comprehensive Cancer Centres. http://www.cancerregistry.nl. Accessed 8 Aug 2010
2. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D (Pubitemid 17231334)
3. DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich MF Press 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 2470152 10.1126/science.2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D (Pubitemid 19147683)
4. M Dowsett J Bartlett IO Ellis J Salter M Hills E Mallon AD Watters T Cooke C Paish PM Wencyk SE Pinder 2003 Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres J Pathol 199 418 423 12635131 10.1002/path.1313 1:CAS:528:DC%2BD3sXlt1Sgtrc%3D (Pubitemid 36411217)
5. N Dendukuri K Khetani M McIsaac J Brophy 2007 Testing for Her2-positive breast cancer: a systematic review and cost-effectiveness analysis CMAJ 176 1429 1434 17485695 10.1503/cmaj.061011 (Pubitemid 46762020)
6. EH Romond EA Perez J Bryant VJ Suman CE Geyer, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
7. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528: DC%2BD2MXhtFansr3L (Pubitemid 41464705)
8. National Breast Cancer Organization of The Netherlands. Guideline breast cancer. http://www.oncoline.nl. Accessed 8 Aug 2010
9. Wittekind C, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH (2004) TNM Atlas, 5th edn. Springer-Verlag, Berlin
10. M Bilous M Dowsett W Hanna J Isola A Lebeau A Moreno F Penault-Llorca J Ruschoff G Tomasic M vd Vijver 2003 Current perspectives on HER2 testing: a review of national testing guidelines Mod Pathol 16 2 173 182 12591971 10.1097/01.MP.0000052102.90815.82 (Pubitemid 36245750)
11. H Yaziji L Goldstein T Barry R Werling H Hwang GK Ellis JR Gralow RB Livingston AM Gown 2004 Her-2 testing in breast cancer using parallel tissue-based methods JAMA 291 1972 1977 15113815 10.1001/jama.291.16.1972 1:CAS:528:DC%2BD2cXjs1ajtrk%3D (Pubitemid 38544278)
12. JMS Bartlett IO Ellis M Dowsett EA Mallon DA Cameron S Johnston E Hall R A'Hern C Peckitt JM Bliss L Johnson P Barrett-Lee P Ellis 2007 Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER)-negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy J Clin Oncol 25 4423 4430 17906205 10.1200/JCO.2007.11.0973 (Pubitemid 350013848)
13. EA Perez VJ Suman NE Davidson S Marino PA Kaufman WL Lingle PF Flynn JN Ingle D Visscher RB Jenkins 2006 HER2 Testing by local, central, and reference laboratories in specimens from the North Central treatment group N9831 intergroup adjuvant trial J Clin Oncol 24 3032 3038 16809727 10.1200/JCO.2005.03.4744 (Pubitemid 46638937)
14. S Paik J Bryant E Tan-Chiu E Romond W Hiller K Park A Brown G Yothers S Anderson R Smith L Wickerham N Wolmark 2002 Real-world performance of HER2 testing-national surgical adjuvant breast and bowel project experience J Natl Cancer Inst 94 852 854 12048273 (Pubitemid 34705057)